Miller E, Waight P, Efstratiou A, Brisson M, Johnson A, George R
Immunization Division, Communicable Disease Surveillance Centre, London.
Acta Paediatr Suppl. 2000 Dec;89(435):11-6. doi: 10.1111/j.1651-2227.2000.tb00776.x.
The results of enhanced national surveillance of pneumococcal disease in children < 15 y of age in England and Wales are reported for the period 1996-1998. Of the 1985 cases of laboratory-confirmed invasive disease (annual incidence 6.6 per 100,000 overall and 39.7 per 100,000 in infants < 1 y of age), 485 (24%) were meningitis (annual incidence of 1.6 per 100,000 overall and 15.7 per 100,000 in infants <1 y of age). Fifty-nine deaths in children with invasive disease were identified-3% of the total reports. Thirty-one different serogroups/types were identified, with organisms in the 7-valent conjugate vaccine responsible for 69% of the infections in children < 5 y of age: this rose to 77% and 82%, respectively, for the 9-and 11-valent vaccines. Resistance to penicillin varied from 2.3% to 6.2% in different years, but erythromycin resistance remained constant at 17%. The vast majority of resistant isolates were in vaccine serotype/groups. Computerized hospital admission records for all children < 15 y of age with a discharge diagnosis code indicating probable pneumococcal disease were also analysed for 1997. The annual incidence for cases with a code specifically mentioning S. pneumoniae was 9.9 per 100,000 compared with 71.2 per 100,000 for lobar pneumonia; the mean duration of stay for both was < 1 wk. The incidence of admission for pneumococcal meningitis (1.9 overall and 19.6 for infants < 1 y of age) was similar to that derived from laboratory reports and resulted in an average duration of stay of 2 wk.
This surveillance has confirmed the substantial burden of morbidity attributable to pneumococcal disease in British children and the potential public health benefits that could be achieved by the use of pneumococcal conjugate vaccines.
报告了1996 - 1998年期间英格兰和威尔士15岁以下儿童肺炎球菌疾病强化国家监测结果。在1985例实验室确诊的侵袭性疾病病例中(总体年发病率为每10万例6.6例,1岁以下婴儿年发病率为每10万例39.7例),485例(24%)为脑膜炎(总体年发病率为每10万例1.6例,1岁以下婴儿年发病率为每10万例15.7例)。确定了59例侵袭性疾病儿童死亡病例,占报告总数的3%。鉴定出31种不同的血清群/类型,7价结合疫苗中的病原体导致5岁以下儿童69%的感染:9价和11价疫苗的这一比例分别升至77%和82%。不同年份对青霉素的耐药率在2.3%至6.2%之间变化,但红霉素耐药率保持在17%不变。绝大多数耐药菌株属于疫苗血清型/群。还分析了1997年所有15岁以下出院诊断代码表明可能患有肺炎球菌疾病儿童的计算机化住院记录。明确提及肺炎链球菌的代码病例年发病率为每10万例9.9例,而大叶性肺炎为每10万例71.2例;两者的平均住院时间均小于1周。肺炎球菌脑膜炎的入院发病率(总体为1.9,1岁以下婴儿为19.6)与实验室报告得出的发病率相似,平均住院时间为2周。
该监测证实了英国儿童肺炎球菌疾病所致发病负担沉重,以及使用肺炎球菌结合疫苗可实现的潜在公共卫生效益。